The randomized controlled study of Lianhuaqingwen capsule in treating A/H1N1 influenza
LIU Geng-xin ZHANG Yan-xia,YANG Ji-qing,et al.* The Third People's Hospital of Langfang City,Hebei,Langfang 065000,China
Objective To observe the efficacy and safety of Lianhuaqingwen capsule in treating A/H1 N1 influenza. Methods In a randomized,open and positive drug controlled study,the 124 cases of viral nucleic acid testing positive for influenza A/H1N1 influenza in hospitalized patients were randomly divided into two groups.The test group was 64 cases,taking Lianhuaqingwen capsule,4 pills once,3 times a day,while the control group was 60 cases, taking oseltamivir phosphate,75 mg once,2 times a day,the course of treatment lasted five days.Detected viral nucleic acid and recorded the main flu-like symptoms during the treatment period.The viral nucleic acid clearance time and the response duration of influenza-like symptoms were observed in all patients.Safety evaluation were carried out through blood,urine,feces routine,biochemistry and ECG.Results The patients of the two groups had no statistical differences in sex and age composition,body temperature,cough,sore throat,headache,fatigue,body aches and other flu-like symptoms(P0.05),baseline data was balanced and comparable,viral nucleic acid clearance time of Lianhuaqingwen capsule treatment group was(4.1±1.7) days,while in oseltamivir treatment group was(3.9±1.7) days,there had no significant statistical difference between the two groups(P0.05).Response duration of cough, sore throat,fatigue,and body ache of test group was significantly shorterthan that in control group,and there was statistical difference between the two groups(P0.05).During the treatment period,no drug-related laboratory abnormalities and adverse events carried out in test group.Conclusion It proved that the Lianhuaqingwen capsule had significant clinical effect and good security in treating A/H1N1 influenza.